(NYSE: OGN) Organon & Co's forecast annual revenue growth rate of 1.11% is not forecast to beat the US Drug Manufacturers - General industry's average forecast revenue growth rate of 7.85%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 13.61%.
Organon & Co's revenue in 2026 is $6,216,000,000.On average, 9 Wall Street analysts forecast OGN's revenue for 2026 to be $1,625,410,918,600, with the lowest OGN revenue forecast at $1,572,566,841,650, and the highest OGN revenue forecast at $1,695,956,459,750. On average, 9 Wall Street analysts forecast OGN's revenue for 2027 to be $1,652,483,746,200, with the lowest OGN revenue forecast at $1,578,293,785,950, and the highest OGN revenue forecast at $1,760,254,425,300.
In 2028, OGN is forecast to generate $1,670,445,526,050 in revenue, with the lowest revenue forecast at $1,590,268,305,850 and the highest revenue forecast at $1,793,835,144,150.